Clinical Trials Directory

Trials / Conditions / Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

20 registered clinical trials studyying Locally Advanced or Metastatic Breast Cancer — 11 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
NCT07461454
MediLink Therapeutics (Suzhou) Co., Ltd.Phase 3
RecruitingA Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Meta
NCT07354022
Shandong Suncadia Medicine Co., Ltd.Phase 3
Not Yet RecruitingA Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Brea
NCT07235618
Sun Yat-sen UniversityPhase 2
Not Yet RecruitingAntibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.
NCT07294430
UNICANCERPhase 2
Not Yet RecruitingA Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cance
NCT06788197
Henan Cancer HospitalPhase 1 / Phase 2
Active Not RecruitingA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanc
NCT06764186
AstraZenecaPhase 3
RecruitingA Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Adv
NCT06680921
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
RecruitingA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
NCT06439771
MediLink Therapeutics (Suzhou) Co., Ltd.Phase 2
RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or M
NCT05860465
Shanghai Pharmaceuticals Holding Co., LtdPhase 2 / Phase 3
RecruitingPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatme
NCT05744687
Shanghai Pharmaceuticals Holding Co., LtdPhase 2 / Phase 3
Active Not RecruitingA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzuma
NCT05296798
Hoffmann-La RochePhase 3
RecruitingUtidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399
Sun Yat-sen UniversityPhase 3
UnknownWeekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
NCT05403333
Fudan UniversityPhase 2
WithdrawnTo Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Bre
NCT05212701
Dompé Farmaceutici S.p.APhase 2
Not Yet RecruitingUtidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Br
NCT05172518
Sun Yat-sen UniversityPhase 3
CompletedGB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
NCT05054751
Genor Biopharma Co., Ltd.Phase 3
CompletedEvaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 M
NCT03781063
Sermonix Pharmaceuticals Inc.Phase 2
CompletedA Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
NCT03437083
Eisai Korea Inc.—
CompletedIncidence and Resolution of Eribulin-Induced Peripheral Neuropathy
NCT03027245
Eisai GmbH—
TerminatedPhase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal G
NCT00634088
R-PharmPhase 1